Benaroya Research Institute (BRI) is on a mission to predict, prevent, reverse and cure immune system diseases. We study the cells and processes within the immune system, how and why immune system diseases start, and how to rebalance the immune system back to health. Our focus spans a wide variety of immune system diseases – including autoimmune diseases, asthma, allergy, cancer and COVID-19 – with the goal of transforming our understanding of how to prevent and treat these conditions.
Collaboration defines our work. We build teams within our institute and with partners around the world to take on some of the most difficult questions in immunology. This approach moves us closer to our vision of a healthy immune system for everyone.
Our Centers of Discovery: A pipeline from lab research to life-changing care
BRI’s research is organized around four Centers of Discovery, allowing us to accelerate advances at every stage of our work. Our centers enable us to make discoveries in the lab and provide a foundation for new and innovative therapies. They also help us to take questions directly from the clinic — such as what makes a therapy work for one person and not another — back to our labs to find meaningful answers.
Our Biorepositories
BRI is home to 11 biorepositories with thousands of blood and tissue samples that have been donated to science, spanning 20 different immune system diseases as well as healthy controls. Access to human samples allows us to closely study diseases in the lab, make new insights, and bring those insights to patient care faster.
Our Core Labs: Building and using the latest tools and technologies
Our Core Labs enable our scientists to build and use some of the most innovative tools in immunology that allow for advanced imaging, data sequencing and exploring the human genome. Each core is led by an expert in their field. Scientists across BRI and from other institutes can partner with these experts to leverage these tools and fuel discoveries in all areas of research.
Our Team: Together we discover
Collaboration is one of BRI’s core values, and our team is our biggest asset. We have built our organization to facilitate teamwork across disease areas, with experts working across fields and with partners around the globe. Shared resources like our Core Labs, Clinical Research Center and biorepositories fuel discoveries across our institute.
Featured Publications
Mar 2025
A molecular basis for milk allergen immune recognition in eosinophilic esophagitis.
J Allergy Clin Immunol
Dilollo J, Hu A, Qu H, Canziani KE, Clement RL, McCright SJ, Shreffler WG, Hakonarson H, Spergel JM, Cerosaletti K, Hill DA
Mar 2025
A coding single nucleotide polymorphism in the interleukin-6 receptor enhances IL-6 signalling in CD4 T cells and predicts treatment response to tocilizumab in giant cell arteritis.
Ann Rheum Dis
Zorc R, Redmond C, Sylvester M, Maclean M, Yamamoto de Almeida L, Quinn KA, Tomelleri A, Campochiaro C, Dagna L, Gutierrez-Rodrigues F, Wells KV, Rankin C, Hait SH, Palmer C, Corty R, Bick A, Lambert K, Buckner JH, O'Shea JJ, Park JK, Gadina M, Grayson PC
Mar 2025
A systematic review of machine learning-based prognostic models for acute pancreatitis: Towards improving methods and reporting quality.
PLoS Med
Critelli B, Hassan A, Lahooti I, Noh L, Park JS, Tong K, Lahooti A, Matzko N, Adams JN, Liss L, Quion J, Restrepo D, Nikahd M, Culp S, Lacy-Hulbert A, Speake C, Buxbaum J, Bischof J, Yazici C, Evans-Phillips A, Terp S, Weissman A, Conwell D, Hart P, Ramsey M, Krishna S, Han S, Park E, Shah R, Akshintala V, Windsor JA, Mull NK, Papachristou G, Celi LA, Lee P
Mar 2025
Considerations for more actionable consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Reply to Mallone R [letter].
Diabetologia
Phillip M, Achenbach P, Addala A, Albanese-O'Neill A, Battelino T, Bell KJ, Besser REJ, Bonifacio E, Colhoun HM, Couper JJ, Craig ME, Danne T, de Beaufort C, Dovc K, Dutta S, Ebekozien O, Elding Larsson H, Frohnert BI, Gallagher MP, Greenbaum CJ, Griffin KJ, Hagopian W, Haller MJ, Hendriks E, Holt RIG, Ismail HM, Jacobsen LM, Kolb LE, Kordonouri O, Lange K, Lash RW, Lernmark A, Libman I, Lundgren M, Maahs DM, Marcovecchio ML, Mathieu C, Oron T, Patil SP, Rewers MJ, Rich SS, Schatz DA, Schulman-Rosenbaum R, Simmons KM, Sims EK, Skyler JS, Speake C, Steck AK, Tonyushkina KN, Veijola R, Wentworth JM, Wherrett DK, Wood JR, Ziegler AG, DiMeglio LA
Mar 2025
Defining a novel DYRK1A-gp130/IL-6R-pSTAT axis that regulates Th17 differentiation.
Immunohorizons
Malueg M, Moo KG, Arnett A, Edwards TH, Ruskin SL, Lambert K, Subramanyam A, Dufort MJ, Gersuk VH, Partridge R, Buckner JH, Khor B
